Innocan Pharma management commentary cites lower online sales as revenue falls to US$11.72 million in H1 2026 - INNPF News | RalliesInnocan Pharma management commentary cites lower online sales as revenue falls to US$11.72 million in H1 2026
I
INNPF• H1 2026 results
- In management commentary for the three and six months ended June 30, 2026, revenue fell to USD 11.72 million from USD 14.8 million.
- Lower online sales volumes drove the decline, reflecting challenging market conditions despite portfolio and marketing initiatives.
- Gross profit margin rose 1.2% for the six-month period, attributed to supply-chain optimization and cost savings.
- Net loss widened to USD 1.04 million from USD 544,000, reflecting weaker revenue and higher general and administrative expense.
- Cash was USD 6.4 million; working capital was USD 8.38 million, down from USD 9.47 million at year-end.
NTRP
•
